CClinicalTrials.gg
Status unknownNCT02408835Updated Apr 6, 2015

Negative Pressure Wound Therapy in Groin Dissection

An interventional study of PICO™ in Neoplasm Metastasis, Secondary Malignant Neoplasm of Lymph Node and Non-healing Surgical Wound (Disorder), sponsored by South Eastern Health and Social Care Trust. Status unknown at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-06.

Sponsored by South Eastern Health and Social Care Trust · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2015), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study investigates the use of a negative pressure wound therapy device (PICO™, Smith \& Nephew Healthcare, UK) on clean, closed surgical wounds, in patients who are undergoing inguinal lymphadenectomy for metastatic carcinoma of cutaneous origin.

Read the detailed description

Patients may develop inguinal lymph node metastases from a variety of cutaneous neoplasms. A number of factors conspire to cause a high rate of wound breakdown and other complications in this patient group. Reported rates of wound healing complications vary in the literature, but tend to affect > 40% of patients.

A new negative pressure wound therapy device is recommended for use in clean, closed surgical wounds (PICO™ system, Smith \& Nephew Healthcare, UK). Patients will be randomised to receive either PICO™ system for up to seven days, or conventional dressings, and then assessed for wound healing and other outcome measures.

02

Conditions studied

  • Neoplasm Metastasis
  • Secondary Malignant Neoplasm of Lymph Node
  • Non-healing Surgical Wound (Disorder)
  • Skin Neoplasms

Keywords

  • negative pressure wound therapy
  • lymphadenectomy
  • wound healing
03

In context

Neoplasms

9,359 studies on the registry are indexed under Neoplasms; 2,486 are open to participants now.

This study's planned enrollment of 22 is below the median of 50 across 7,250 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

South Eastern Health and Social Care Trust is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Histologically- or cytologically-proven inguinal lymph node metastases from neoplasm of cutaneous origin

Exclusion criteria

Exclusion Criteria:

  • inability to give informed consent for participation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Active comparator
    PICO™

    Use of PICO™ system negative pressure wound therapy device on surgical wound for up to seven days.

    Device: PICO™

  • No intervention
    Conventional wound care

    Usual wound dressings will be used as comparison group.

Interventions

  • DevicePICO™

    Negative pressure wound therapy device for closed surgical wounds.

    Also known as: PICO™, Smith & Nephew Healthcare, UK

06

What researchers measure

Primary outcomes

  1. Time to wound healing

    Determination of wound healing

    Time frame: From date of surgery until epithelial integrity is restored at the surgical site. Assessed at least weekly until wound is healed, up to 20 weeks after surgery

Secondary outcomes

  1. Wound infection As defined by Comprehensive Complication Index (CCI)

    As defined by Comprehensive Complication Index (CCI)

    Time frame: From date of surgery until wound is healed (epithelial integrity restored at surgical site), up to 20 weeks after surgery.

  2. Lymphoedema (Limb volume measurements)

    Limb volume measurements at 3, 6, 9 and 12 months

    Time frame: From date of surgery up to one year post-operatively.

  3. Need for further surgical interventions to achieve wound healing

    Time frame: From date of surgery until wound is healed, up to 20 weeks after surgery.

  4. Scar appearance (POSAS)

    POSAS at 3,6, 9 and 12 months

    Time frame: From date of surgery up to one year post-operatively.

  5. Patient reported outcomes (qualitative interview)

    Semi-structured qualitative interviews in first week after surgery, and at 6 months after surgery.

    Time frame: From date of surgery to six months post-operatively.

07

Study locations

1 site
  • The Ulster Hospital
    Belfast, Northern Ireland BT16 1RH, United Kingdom
    • Sandra E McAllister, MD · Contact · s.mcallister@qub.ac.uk · +442890484511
    • Christopher Hill, MB · Principal investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02408835
Lead sponsor
South Eastern Health and Social Care Trust
Responsible party
Sandra McAllister (Academic Clinical Lecturer, South Eastern Health and Social Care Trust) — Principal investigator
First posted
Apr 6, 2015
Start date
Jul 2015
Primary completion
Jul 2019 (estimated)
Completion
Jul 2019 (estimated)
Last update
Apr 6, 2015

Study contacts

Sandra E McAllister, MD
Contact
s.mcallister@qub.ac.uk
02890484511
Christopher Hill, MB
Contact
02890484511
Christopher Hill, MB
study chair · South Eastern Health & Social Care Trust

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion